These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 20371505)

  • 21. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis.
    Sfikakis PP; Papamichael C; Stamatelopoulos KS; Tousoulis D; Fragiadaki KG; Katsichti P; Stefanadis C; Mavrikakis M
    Arthritis Rheum; 2007 Jun; 56(6):1985-93. PubMed ID: 17530638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-healing ischaemic digital ulcer in a systemic sclerosis patient: a challenging clinical case.
    Blaise S; Roustit M; Forli A; Imbert B; Cracowski JL
    Int Wound J; 2017 Dec; 14(6):978-981. PubMed ID: 28303689
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and tolerability of bosentan for digital ulcers in Japanese patients with systemic sclerosis: Prospective, multicenter, open-label study.
    Hamaguchi Y; Sumida T; Kawaguchi Y; Ihn H; Tanaka S; Asano Y; Motegi SI; Kuwana M; Endo H; Takehara K
    J Dermatol; 2017 Jan; 44(1):13-17. PubMed ID: 27374274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bosentan for digital ulcers in patients with systemic sclerosis.
    Nagai Y; Hasegawa M; Hattori T; Okada E; Tago O; Ishikawa O
    J Dermatol; 2012 Jan; 39(1):48-51. PubMed ID: 21955007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial.
    Prey S; Ezzedine K; Doussau A; Grandoulier AS; Barcat D; Chatelus E; Diot E; Durant C; Hachulla E; de Korwin-Krokowski JD; Kostrzewa E; Quemeneur T; Paul C; Schaeverbeke T; Seneschal J; Solanilla A; Sparsa A; Bouchet S; Lepreux S; Mahon FX; Chene G; Taïeb A
    Br J Dermatol; 2012 Nov; 167(5):1138-44. PubMed ID: 23039171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
    Denton CP; Humbert M; Rubin L; Black CM
    Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bosentan in systemic sclerosis.
    Heresi GA; Minai OA
    Drugs Today (Barc); 2008 Jun; 44(6):415-28. PubMed ID: 18596996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bosentan in clinical practice for treating digital and other ischemic ulcers in Spanish patients with systemic sclerosis: IBER-DU cohort study.
    Roman Ivorra JA; Simeon CP; Alegre Sancho JJ; Egurbide MV; Castillo MJ; Lloria X; Fonollosa V
    J Rheumatol; 2011 Aug; 38(8):1631-5. PubMed ID: 21632679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers.
    Jain M; Varga J
    Expert Opin Pharmacother; 2006 Aug; 7(11):1487-501. PubMed ID: 16859432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bosentan for digital ulcers in patients with systemic sclerosis: a prospective 3-year followup study.
    Tsifetaki N; Botzoris V; Alamanos Y; Argyriou E; Zioga A; Drosos AA
    J Rheumatol; 2009 Jul; 36(7):1550-2. PubMed ID: 19567637
    [No Abstract]   [Full Text] [Related]  

  • 31. Effects of bosentan on nondigital ulcers in patients with systemic sclerosis.
    Taniguchi T; Asano Y; Hatano M; Tamaki Z; Tomita M; Kawashima T; Miyazaki M; Sumida H; Akamata K; Takahashi T; Ichimura Y; Toyama T; Sugita M; Noda S; Yao A; Kinugawa K; Sato S
    Br J Dermatol; 2012 Feb; 166(2):417-21. PubMed ID: 21848685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of digital ulcers in systemtic sclerosis with endothelin-1 receptor antagonist (bosentan)].
    Riccardi MT; Chialà A; Lannone F; Grattagliano V; Covelli M; Lapadula G
    Reumatismo; 2007; 59(2):135-9. PubMed ID: 17603693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the effect of Bosentan treatment on proinflammatory cytokine serum levels in patients affected by Systemic Sclerosis.
    Bellisai F; Morozzi G; Scaccia F; Chellini F; Simpatico A; Pecetti G; Galeazzi M
    Int J Immunopathol Pharmacol; 2011; 24(1):261-4. PubMed ID: 21496413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial.
    Khanna D; Furst DE; Clements PJ; Park GS; Hays RD; Yoon J; Korn JH; Merkel PA; Rothfield N; Wigley FM; Moreland LW; Silver R; Steen VD; Weisman M; Mayes MD; Collier DH; Medsger TA; Seibold JR; ;
    J Rheumatol; 2005 May; 32(5):832-40. PubMed ID: 15868618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insulin resistance is associated with digital ulcer in patients with systemic sclerosis.
    Park EK; Lee SG; Kim BH; Park JH; Lee S; Kim GT
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):85-91. PubMed ID: 27383539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Digital ulcers in systemic sclerosis : A retrospective heath service study analysing treatment with bosentan and other vasoactive therapies].
    Riemekasten G; Beissert S; Distler JH; Kreuter A; Müller-Ladner U
    Z Rheumatol; 2017 Apr; 76(3):228-237. PubMed ID: 27535277
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bosentan and sildenafil: successful treatment in a sclerodermic patient with refractory ulcers.
    Catarsi E; Doveri M; Tavoni A
    Reumatismo; 2013 May; 65(2):79-81. PubMed ID: 23877412
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.
    McLaughlin VV
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():10-5. PubMed ID: 16919005
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world effectiveness and safety of bosentan in Japanese patients with systemic sclerosis: A single-center retrospective study.
    Ishikawa M; Endo Y; Yamazaki S; Sekiguchi A; Uchiyama A; Motegi SI
    J Dermatol; 2023 Jun; 50(6):828-832. PubMed ID: 36651000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized, blinded, parallel group, placebo controlled pilot study evaluating the effect of PVAC treatment in patients with diffuse systemic sclerosis.
    Genovese MC; Chakravarty EF; Boyle DL; Tutuncu Z; Thorburn CM; Halilhodzic M; Kroll S; Baughman J; Stewart S; Kavanaugh A
    J Rheumatol; 2005 Dec; 32(12):2345-50. PubMed ID: 16331761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.